Abstract. Excessive stretching of the vascular wall in accordance with pulmonary arterial hypertension (PAH) induces a variety of pathogenic cellular events in the pulmonary arteries. We previously reported that indoxam, a selective inhibitor for secretory phospholipase A 2 (sPLA 2 ), blocked the stretch-induced contraction of rabbit pulmonary arteries by inhibition of untransformed prostaglandin H 2 (PGH 2 ) production. The present study was undertaken to investigate involvement of sPLA 2 and untransformed PGH 2 in the enhanced contractility of pulmonary arteries of experimental PAH in rats. Among all the known isoforms of sPLA 2 , sPLA 2 -X transcript was most significantly augmented in the pulmonary arteries of rats with monocrotaline-induced pulmonary hypertension (MCT-PHR). The pulmonary arteries of MCT-PHR frequently showed two types of spontaneous contraction in response to stretch; 27% showed rhythmic contraction, which was sensitive to indoxam and SC-560 (selective COX-1 inhibitor), but less sensitive to NS-398 (selective COX-2 inhibitor); and 47% showed sustained incremental tension (tonic contraction), which was insensitive to indoxam and SC-560, but sensitive to NS-398 and was attenuated to 45% of the control. Only the rhythmically contracting pulmonary arteries of MCT-PHR produced a substantial amount of untransformed PGH 2 , which was abolished by indoxam. These results suggest that sPLA 2 -mediated PGH 2 synthesis plays an important role in the rhythmic contraction of pulmonary arteries of MCT-PHR.
Introduction
It has been well documented that hemodynamic forces affect a variety of cellular functions involved in the homeostasis of the cardiovascular system (1) . Pulmonary circulation is a low pressure side (< 10 mmHg) as compared with the relatively high pressure systemic side (> 60 mmHg); however, mid-and long-term increase in pulmonary artery blood pressure seen in pulmonary arterial hypertension (PAH) is associated with a variety of pathological conditions of the arteries such as increased vascular tone, pulmonary vascular remodeling, and pulmonary vascular inflammation (2, 3) . We have shown that mechanical stretching of isolated pulmonary arteries from normal rabbits and rats induced a variety of cellular events, including smooth muscle contraction, production of vasoactive prostaglandins (PGs) (4), activation of protein tyrosine phosphorylations (5) , and gene expression (5) . Because these events are involved in functional and/or phenotypical changes of blood vessels, we consider that the stretching of the artery might partly mimic cellular mechanisms for pathogenicity of the pulmonary artery in PAH.
The stretching of normal rabbit pulmonary artery rapidly induced a vasoconstriction by the production of untransformed PGH 2 , which was mainly derived from endothelium (4) . We recently reported that a secretory phospholipase A 2 (sPLA 2 )-mediated pathway was involved in this mechanism (6) . However, there was no direct evidence concerning the role of untransformed PGH 2 and sPLA 2 in the pulmonary arteries of PAH. We indicate here that the release of untransformed PGH 2 is closely associated with aberrant function (rhythmic contraction) of endothelium-denuded pulmonary arteries of monocrotaline-induced PAH rats (MCT-PHR). The pulmonary arteries of MCT-PHR highly express group X sPLA 2 isoform (sPLA 2 -X), and the rhythmic contraction is specifically inhibited by indoxam, a selective sPLA 2 inhibitor. These results suggest that sPLA 2 could be a potential target for pharmacological regulation of possible dysfunction in pulmonary artery of MCT-PHR.
Materials and Methods

Animal handling and preparation of pulmonary arteries of rats
The present study was performed according to the Guideline for the Care and Use of Laboratory Animals of The Japanese Pharmacological Society and was approved by the Institutional Animal Care and Use Committees of University of Shizuoka and Iwate Medical University.
A total of 113 male Sprague-Dawley rats (94 monocrotaline-injected rats and 19 saline-injected rats) were used (Japan SLC, Shizuoka). The rats at 5 weeks of age were injected subcutaneously with either MCT (60 mg·kg −1 ) or saline. On day 21 after the single injection, each rat was euthanized under anesthesia with sodium pentobarbital (50 mg·kg −1 ), and a 2-mm-wide ring in the first branch of the pulmonary artery was prepared as described previously (4 -8) . Establishment of PAH in the MCT-injected rats was routinely checked for right ventricular hypertrophy [weight ratio of RV·(LV + septum) −1 ] and elevation of right ventricular systolic pressure (RVSP) as described previously (9) .
Recording of isometric tension and stretch activation of pulmonary artery
Mechanical stimulation and measurement of isometric contraction of pulmonary arteries were described previously (4 -8) . Briefly, each rat artery ring, mounted on a tension-measuring-apparatus, was incubated in KrebsHenseleit bicarbonate solution (KHB) aerated with 95% O 2 / 5% CO 2 at 37°C. An initial muscle length (L i = 100%) was determined as the circumference of the ring preparation at which detectable passive tension had just begun to appear. The ring segment was stretched by a micromanipulator at a rate of approximately 0.5 mm·s −1 to give its passive isometric tension of about 15 mN. The average degree of the stretch was 214% ± 15% (2.14 × L i ), which was theoretically equivalent to a transmural pressure of 40 mmHg (5) .
Measurement of untransformed PGH 2 production
Release of untransformed PGH 2 was estimated by measuring the difference in the PGF 2α level between the bathing solution before and after addition of SnCl 2 as described previously (4, 6, 10) . As the stretch-induced production of untransformed PGH 2 is mediated by the RGD-peptide-insensitive pathway (4, 6) , 100 μM GlyArg-Gly-Asp-Ser-Pro (GRGDSP) was added to the bathing solution of the pulmonary arteries. In this condition, measurable PGF 2α was only derived from untransformed PGH 2 , because stretch-induced PGF 2α in a nonreducing condition (i.e., without SnCl 2 ) was completely blocked by RGD-peptide (4, 6) . For the measurement of untransformed PGH 2 , bathing solution was collected in the following order: The pulmonary artery ring at L i was incubated for 5 min in 2 ml of the bathing solution (basal), and then stretched for 5 min in fresh 2 ml of the bathing solution (stretch). The artery was again subjected to the sequential incubation of 5 min at L i (basal + SnCl 2 ) and the stretched condition (stretch + SnCl 2 ) in 2 ml each of fresh bathing solution containing 1.05 mM SnCl 2 .
Quantitation of rat transcripts
Extraction of total RNA from rat tissues and cDNA synthesis were performed as described previously (11, 12) . Level of transcript for each sPLA 2 isoform was determined quantitatively by reverse transcription and real-time PCR using oligonucleotide primers (Table 1) and the SYBR-Premix Ex Taq PCR kit (Takara Bio, Inc., Otsu) and ABI 7500 (Applied Biosystems, Foster City, CA, USA). For the relative quantification of gene expressions, cDNA of rat lung total RNA was serially diluted in order to create standard curves. Furthermore, absolute quantification of each cDNA in the pulmonary arteries of both normal rat and MCT-PHR was carried out. For this purpose, specific controls were constructed by cloning of partial or full-length cDNAs for various sPLA 2 s, COXs, and β-actin into pGEM-T easy vector (Promega Corp., Madison, MI, USA). Nucleotide sequences of cloned products were confirmed by DNA sequencing. Concentration (μg/ml) of purified plasmid DNA was quantified by combination of spectrophotometry and agarose gel electrophoresis, and then the copy number of the standard cDNA was calculated as follows: copy number of double stranded standard plasmid DNA = mol × N A = (weight in g) / [(length of plasmid in bp) × 660] × N A , where N A means Avogadro's number (6.02 × 10 23 ). The copy number of the first strand cDNA in the reverse transcription cocktail can be calculated as 2 × (copy number of double stranded standard cDNA).
Real-time PCR was carried out in a PCR amplification mixture of 10 μl containing 1st strand cDNA derived from 20 ng of total RNA, 5 pmol each of forward and reverse primers, and 5 μl of SYBR Premix Ex Taq with the following temperature cycling: polymerase-activation at 95°C for 15 min and amplification of 40 cycles: 15 s at 94°C, 20 s at 60°C, 40 s at 72°C. After amplification, dissociation curve analysis was performed by the ABI 7500 standard program. All PCR products were analyzed by polyacrylamide and/or agarose gel electrophoresis.
Western blot analysis
The pulmonary artery including main trunk and first branch was isolated and quickly frozen by immersing in liquid nitrogen. Frozen tissue was then pulverized and homogenized with a high-speed tissue homogenizer (Physcotron; Nichion-Rikakiki, Chiba) in ice-cold homogenization buffer (50 mM tris-HCl, pH 7.5, 1 mM EDTA, 100 mM NaCl), supplemented with protease inhibitors (Protease inhibitor mixture #160-19501, 1:1000 diluted; Wako Pure Chemical Industries, Osaka). The concentration of protein in each sample was determined by BCA protein assay kit (#23227; Pierce, Rockford, IL, USA). The tissue extract containing an equal amount of protein was resolved by 15% SDS-polyacrylamide gel electrophoresis under reducing conditions. Protein was transferred to a 0.2-μm microporous PVDF membrane (Immobilon Psq; Millipore, Bedford, MA, USA), and the membrane was blocked with 5% skim milk in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% Tween-20 (TBST150). Western blot analysis was then carried out using either anti-sPLA 2 -X antibody (#H00008399-D01P; Abnova, Taipei, Taiwan) or anti-α-tubulin polyclonal antibody (#sc-12462; Santa Cruz Biotechnology, Santa Cruz, CA, USA). These primary antibodies and speciesmatched secondary antibodies conjugated with horseradish peroxidase (Sigma-Aldrich, St. Louis, MO, USA) were diluted 1:5000 with Max Blot (Medical and Biological Laboratories, Co., Ltd., Nagoya). The membrane was extensively washed with 20 mM tris-HCl (pH 7.4), 300 mM NaCl, and 0.1% Tween-20 (TBST300). Immunoreactive band was visualized using the SuperSignal West Femto Maximum Sensitivity Substrate (#34096; Thermo Scientific, Rockford, IL, USA) and was analyzed by the LAS-3000 imaging system (Fujifilm Co., Tokyo).
Drugs and chemicals
Indoxam, a specific inhibitor for sPLA 2 (13, 14) , 
Statistics
The data are expressed as the mean ± S.E.M. Statistical analyses were done by the paired or unpaired t-test for comparison between two groups, the Tukey-Kramer test or Williams' test for multiple comparisons after analysis of variance (ANOVA), and Fisher's exact test for incidence analysis of the rhythmic contraction, as indicated in the figures or tables. Differences were considered statistically significant when P < 0.05.
Results
Enhanced expression of sPLA 2 in the pulmonary artery of MCT-PHR
A significant increase in both RVSP (MCT-PHR, 28.0 ± 3.6 mmHg vs. control, 12.2 ± 0.4 mmHg, P < 0.01) and RV·(LV + S) −1 ratio (MCT-PHR, 0.522 ± 0.010 vs. control, 0.257 ± 0.007, P < 0.01) clearly showed establishment of PAH by MCT-injection. In these rats, relative amounts of sPLA 2 transcripts in pulmonary arteries, whole lungs, and aortae were analyzed quantitatively by reverse transcription and real-time PCR. Among all the known sPLA 2 s, the steady-state level of sPLA 2 -X transcript increased preferentially in the pulmonary arteries of MCT-PHR 21 days after MCT-injection (Fig. 1I ). No such difference was observed in the aortae or lungs of either the MCT-PHR or control groups.
Absolute quantifications of sPLA 2 s, COXs, and β-actin in the pulmonary artery cDNAs were also carried out by real-time PCR with standard curves of plasmids harboring authentic cDNAs ( Table 2 ). The copy numbers of sPLA 2 isoforms in the pulmonary arteries significantly varied, ranging between 10 2 − 10 7 copies/μg total RNA. Among these isoforms, sPLA 2 -X (1 − 2 × 10 3 copies/μg total RNA) and sPLA 2 -IID (1 × 10 5 copies/μg total RNA) showed increased expression in the pulmonary arteries of MCT-PHR. The relative expression levels in the pulmonary arteries of neither COX-1 nor COX-2 showed any appreciable difference between normal rats and MCT-PHR, but the copy number of COX-1 was much more abundant as compared with that of COX-2 in the pulmonary arteries. There was no appreciable difference in the copy number of β-actin between the two groups.
Expression of sPLA 2 -X was also analyzed at the protein level. Specificity of the western blot by anti-human sPLA 2 -X antibody to detect the rat protein was confirmed using rat testis extract ( Fig. 2A) . A doublet of immunoreactive bands of 14 − 15 kDa was also reported in human sPLA 2 -X due to the proteolytic processing of the N-terminal propeptide (15 − 17) . Increased expression of sPLA 2 -X in the pulmonary arteries of MCT-PHR was also detected at the protein level (Fig. 2B) 
Effects of sPLA 2 -and COX-selective inhibitors on stretch-induced contraction of pulmonary artery of MCT-PHR
The effect of mechanical stretch with a passive load of about 15 mN on rat pulmonary arteries, which theoretically corresponds to the transmural pressure in pulmonary hypertension (5), was examined. The pulmonary arteries of normal rats produce a phasic and endothelium-dependent contraction in response to the stretch (Fig. 3: A and B), which was very similar to that observed in the pulmonary arteries of normal rabbits (4, 6, 8) . However, the pulmonary arteries of MCT-PHR showed enhanced contractility with frequent production of oscillatory changes of isometric tension [rhythmic contraction (7) and also confirmed in this study, Fig. 3C ] and/or sustained incremental tension (tonic contraction, Fig. 3D ) in response to the stretch, irrespective of the presence or absence of endothelium. The total of the incidence rate of the rhythmic contraction throughout all the experiments was 27.1% (105 out of total 387 preparations) and the tonic contraction was 46.8% (181 out of total 387 preparations). These characteristic contractions were never observed in the pulmonary arteries of control normal rats [in neither ref. 7 nor in this study].
The rhythmic contraction in the pulmonary artery of MCT-PHR was abolished by 1 − 3 μM indoxam, a selective inhibitor for sPLA 2 s, in all 9 independent preparations tested (Fig. 3A, Table 3 , P < 0.01 by Fisher's exact test). The rhythmic contraction was also abolished by 10 μM SC-560 (Fig. 4B, Table 3 , P < 0.05 by Fisher's exact test), a COX-1 selective inhibitor. In contrast, NS-398, a selective COX-2 inhibitor, was less effective on the rhythmic contraction; in 3 out of 7 independent preparations, 10 μM NS-398 tended to be inhibitory, but had no effect in the remaining 4 preparations (Fig. 4C , summarized in Table 3 ). On the other hand, the tonic contraction was neither affected by indoxam nor by SC-560, but was inhibited to 45% of control by NS-398 (Fig. 5 , A -C, summarized in Table 4 ). None of these inhibitors showed any appreciable effect on 40 mM KCl-induced contraction of pulmonary arteries of MCT-PHR, whereas nicardipine, a L-type Ca 2+ channel blocker, dose-dependently inhibited the KCl-induced contraction (Table 5) .
Selective inhibition of sPLA 2 abolished the untransformed PGH 2 production by pulmonary artery of MCT-PHR
Production of untransformed PGH 2 was negligible in endothelium-denuded pulmonary arteries of normal rats in response to the stretch (Fig. 6A) . Even in the absence of endothelium, however, a significant increase in production of untransformed PGH 2 was detected when the arteries of MCT-PHR showed rhythmic contractions (Fig. 6B) Fig. 1 . Real-time PCR analysis of sPLA2 isoform transcripts in MCT-PHR. Expression of sPLA2 transcripts was examined by quantitative reverse transcription and real-time PCR as described in Materials and Methods. Multiple comparison of the expression levels of each sPLA2-isoform among different tissues of control and MCT-PHR are given: A) sPLA2-IB, B) sPLA2-IIA, C) sPLA2-IIC, D) sPLA2-IID, E) sPLA2-IIE, F) sPLA2-IIF, G) sPLA2-III, H) sPLA2-V, I) sPLA2-X, J) sPLA2-XIIA, and K) sPLA2-XIIB, respectively. Values are expressed as the relative transcript levels (mean lung of control rats = 1) that have been normalized with the level of β-actin transcript. Each value represents a mean ± S.E.M. **P < 0.01 vs. corresponding value by the TukeyKramer test. C, control; M, MCT-PHR; PA, pulmonary arteries; Lg, lungs; Ao, aortae. Western-blot analysis of sPLA2-X protein in the pulmonary arteries of MCT-PHR. A) Specificity of western blot analysis using anti-sPLA2-X antibody. Total proteins (20 μg) from rat testis were analyzed by using anti-sPLA2-X polyclonal antibody or control (preimmune) rabbit IgG. B) Western blot analysis of sPLA2-X protein in rat pulmonary artery tissues. Total proteins (100 μg) from control rats or MCT-PHR on the duplicate blots were probed with anti-sPLA2-X or control rabbit IgG. Detection of α-tubulin on the same blot was also carried out after removal of the initial probes. C1 and C2, pulmonary arteries from different control rats (n = 2); M1, M2, M3, M4, pulmonary arteries from different MCT-PHR (n = 4), respectively. , n = 6) (6), although the difference did not reach statistical significance (P = 0.067). It is worthy to note that untransformed PGH 2 was below a detectable level even in pulmonary arteries of MCT-PHR 44.8 ± 10.1* Each value represents a mean ± S.E.M. Conc., final concentration; n, number of independent pulmonary artery preparations; † † P < 0.01 by the paired t-test and *P < 0.05 by the unpaired t-test vs. corresponding control values.
when the arteries did not produce the rhythmic contraction (data not shown).
Discussion
The present study demonstrated that the expression of sPLA 2 -X was preferentially augmented in the pulmonary arteries of MCT-PHR and that indoxam, a selective sPLA 2 inhibitor, completely reversed the rhythmic contraction through inhibition of untransformed PGH 2 production.
Similar to that observed in normal rabbit pulmonary arteries (4, 6, 8) , a stretch-induced phasic contraction of normal rat pulmonary arteries was also observed in an endothelium-dependent manner (Fig. 3: A and B) . On the other hand, both the stretch-induced rhythmic and tonic contractions were characteristically observed in the pulmonary arteries of MCT-PHR (Fig. 3: C and D) independently of the endothelium. This suggested that certain mechanism(s) for the aberrant and enhanced contractilities were pathogenically augmented in the medial and/or adventitial layers of the pulmonary arteries of MCT-PHR.
The rhythmic contraction of pulmonary artery was reported in different types of PAH models in rats, which is induced by either chronic hypoxia (18) or MCT (7), as well as a 4-day-organoid culture of pulmonary artery in vitro (19) . The ionic mechanism for developing rhythmic contraction has been explained by membrane depolarization activating L-type calcium channels, which is balanced by calcium-activated potassium channel activity (19) and also by calcium-induced calcium release (7, 18) . In addition, we previously suggested that PGH 2 might be involved in the stretch-induced rhythmic contraction of pulmonary arteries of MCT-PHR, because indomethacin and the PGH 2 /thromboxane A 2 receptor antagonist ), which were expressed in the bathing solution containing 100 μM of RGD-peptide. **P < 0.01 (n = 6 -8) by the Tukey-Kramer test; Vehicle, 0.01% DMSO; Indoxam, 10 μM. sPLA2 and Pulmonary Artery in PAH SQ29548 abolished the rhythmic contraction and reduced the tension, but the thromboxane synthase inhibitor ozagrel showed no effect (7). Our recent study using normal rabbit pulmonary arteries (6) demonstrated that untransformed PGH 2 acted as an endothelium-derived contracting factor (EDCF) (20) ; however, in the present study using a rat system, a significant amount of untransformed PGH 2 was actually produced even in the endothelium-denuded pulmonary arteries of MCT-PHR with concomitant rhythmic contraction in response to the stretch (Fig. 3) . Indoxam readily abolished the rhythmic contraction (Fig. 4A) , which was consistent with the complete inhibition of untransformed PGH 2 production (Fig. 6B) .
A striking difference in susceptibility of indoxam and isoform-selective COX inhibitors regarding the enhanced contractilities suggested that the rhythmic contraction was mediated by an indoxam-sensitive mechanism coupled with COX-1 (Fig. 4B) , which is consistent with the dominance in the expression level of COX-1 in the pulmonary artery (Table 2 ). On the other hand, the tonic contraction was mediated by indoxam-and SC-560-insensitve mechanism(s) partially inhibited by NS-398 ( Fig. 5C and Table 4 ), suggesting that this pathway might be partially coupled with COX-2 regardless of its relatively lower expression (Table 2 ). An alternative interpretation about the inhibitory effect of NS-398 on the tonic contraction might be that it is independent from COX-inhibition. This possibility cannot be ruled out at present. The inhibitory effects of indoxam, SC-560, and NS-398 are less likely to be involved in Ca
2+
-antagonistic activity because these compounds did not affect high K + -induced contraction (Table 5) . Consistent with these pharmacological characterizations, untransformed PGH 2 was detected only when the pulmonary arteries of MCT-PHR produced the rhythmic contraction in response to stretch (Fig. 6B) . On the other hand, we could not determine any factors and/or mechanisms involved in the stretch-induced tonic contraction of the pulmonary arteries of MCT-PHR. Because the tonic contraction was completely reversed by replacement of KHB in an organ bath (Fig. 5: A − C), other vasoconstrictive substances including both COX-2-drived factors and non-COX-derived factors would be involved. Further study will be needed to elucidate this mechanism.
Although the expression levels of sPLA 2 isoforms in the pulmonary artery of rats significantly varied (Table  2) , it has been indicated that there are differences in the substrate preference and specific activities of each sPLA 2 (15, 17, 21, 22) . For example, sPLA 2 -IIA, the most abundant isoform in the pulmonary arteries (Table 2) , and sPLA 2 -IID, the moderate abundant isoform with up-regulation in the pulmonary arteries of MCT-PHR (Table 2) , show lower efficiencies to increase arachidonic acid metabolism (15, 17) , which is the adjacent upstream step of PGH 2 synthesis. In contrast, sPLA 2 -X, a relatively low abundant isoform with significant up-regulation of both transcript (Table 2 ) and protein (Fig. 2) in the pulmonary arteries of MCT-PHR, shows higher affinity to phosphatidylcholine than the other types of sPLA 2 s with the highest specific activity in promoting arachidonic acid release from mammalian cells (15, 17, 21, 22) . Enhanced expression of sPLA 2 -X was preferentially observed in the pulmonary arteries of MCT-PHR (Fig. 1) , where the mechanical stress would be significantly higher due to an increased pulmonary artery pressure. These results strongly suggest that overexpression of sPLA 2 -X is pathogenically associated with localized change in the pulmonary circulatory system, including elevated pulmonary artery blood pressure, hyperplasia and/or obstructive changes, and proinflammatory changes in the pulmonary arteries. In any case, the expression of neither COX-1 nor COX-2 was pathogenically altered in the pulmonary arteries of MCT-PHR (Table 2) . Given these observations, it is plausible that overexpression of sPLA 2 -X might be responsible for the aberrant mechanical responses of pulmonary arteries from MCT-PHR, such as rhythmic contraction.
The cellular source of sPLA 2 s in the pulmonary artery involved in the production of untransformed PGH 2 still remains obscure. Although the expression profiles of individual sPLA 2 s in tissues differ according to the animal species and type of pathology, sPLA 2 -X was detectable in normal human lung fibroblasts or bronchial and alveolar epithelium in human lung tissue with mild or no inflammation (17) . However, it significantly increased in atherosclerotic lesions in aorta from apolipoprotein Edeficient mice (23) and in carotid artery or aorta from human patients (24) , and it was especially prominent in multilayered foam cells (23, 24) and phenotypically dedifferentiated smooth muscle cells in the intimal or medial layers (23, 24) . Although sPLA 2 -X might be expressed primarily in the endothelium in normal pulmonary arteries (6), we separately observed that cyclic mechanical stretching significantly upregulated several sPLA 2 isoforms including sPLA 2 -X in cultured rat vascular smooth muscle cells (Y. Tanabe, unpublished data). These results suggested that not only arterio-and/or atherosclerotic changes (25, 26) , but also the mechanical stimuli in pulmonary arteries might play a significant role for the enhanced expression of sPLA 2 transcripts. The exact origin of sPLA 2 -X-producing cells in the pulmonary arteries of MCT-PHR remains to be elucidated.
It has been suggested that a hemodynamic role in the rhythmic contraction leads to development of the PAH in the rat chronic hypoxia model (18) . The effect of untransformed PGH 2 itself would be blocked by use of COX inhibitors and/or receptor antagonists; however, these approaches might be somewhat non-specific irrespective of disease status, leading to undesirable effects including potential cardiovascular risks. In this regard, it has been demonstrated that absence or inhibition of COX-2 exacerbates hypoxia-induced PAH and enhances contractility of VSMCs (27) . Our present study suggests an important role of sPLA 2 in the stretch-induced rhythmic contraction of pulmonary arteries of MCT-PHR. This mechanism would be further exacerbated by enhanced expression of specific sPLA 2 isoforms such as sPLA 2 -X, the most potent arachidonic acid releasing enzyme among various known sPLA 2 s (15, 21) , during the development of PAH. Since the specific sPLA 2 inhibitor could attenuate untransformed PGH 2 production at the upstream step of COXs and reverse the diseaseassociated rhythmic contraction, the blockade of sPLA 2 s, especially sPLA 2 -X, might provide an alternative approach for PAH.
